| Item Type | Name |
|
Concept
|
Transplantation Conditioning
|
|
Academic Article
|
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
|
|
Academic Article
|
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
|
|
Academic Article
|
Autologous and allogeneic transplantation for aggressive NHL.
|
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
|
Academic Article
|
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
|
|
Academic Article
|
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
|
|
Academic Article
|
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
|
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
|
|
Academic Article
|
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
|
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
|
Academic Article
|
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
|
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
|
Academic Article
|
Chimerism does not predict for outcome after alemtuzumab based conditioning.
|
|
Academic Article
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity.
|
|
Academic Article
|
T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter?
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.
|
|
Academic Article
|
Influence of related donor age on outcomes after peripheral blood stem cell transplantation.
|
|
Academic Article
|
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
|
|
Academic Article
|
Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.
|
|
Academic Article
|
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
|
|
Academic Article
|
Nonmyeloablative conditioning for relapsed follicular lymphoma.
|
|
Academic Article
|
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
|
|
Academic Article
|
Stem cell transplantation in follicular lymphoma: progress at last?
|
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned.
|
|
Academic Article
|
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
|
|
Academic Article
|
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.
|
|
Academic Article
|
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
|
|
Academic Article
|
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
|
|
Academic Article
|
Autologous and allogeneic stem cell transplantation in follicular lymphoma.
|
|
Academic Article
|
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
|
|
Academic Article
|
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
|
|
Academic Article
|
Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?
|
|
Academic Article
|
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
|
|
Academic Article
|
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
|
|
Academic Article
|
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.
|
|
Academic Article
|
Allogeneic blood stem cell transplantation in advanced hematologic cancers.
|
|
Academic Article
|
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
|
|
Academic Article
|
Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma.
|
|
Academic Article
|
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
|
|
Academic Article
|
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
|
|
Academic Article
|
Stem cell transplantation for indolent lymphoma: a reappraisal.
|
|
Academic Article
|
Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy.
|
|
Academic Article
|
Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions.
|
|
Academic Article
|
Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
|
|
Academic Article
|
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Superiority of reduced-intensity conditioning for Hodgkin's lymphoma.
|
|
Academic Article
|
Alemtuzumab in allogeneic hematopoetic stem cell transplantation.
|
|
Academic Article
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
|
|
Academic Article
|
Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
|
|
Academic Article
|
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.
|
|
Academic Article
|
Toxicity of high dose BCNU: how much is too much?
|
|
Academic Article
|
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
|
|
Academic Article
|
Reduced-intensity and nonmyeloablative conditioning regimens.
|
|
Academic Article
|
The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma.
|
|
Academic Article
|
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
|
|
Academic Article
|
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
|
|
Academic Article
|
Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum.
|
|
Academic Article
|
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
|
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
|
Academic Article
|
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.
|
|
Academic Article
|
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
|
|
Academic Article
|
Haplo-cord transplant: HLA-matching determines graft dominance.
|
|
Academic Article
|
Haploidentical cord transplantation-The best of both worlds.
|
|
Academic Article
|
Second allogeneic transplantation: ever? never? or sometimes.
|
|
Academic Article
|
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
|
Academic Article
|
Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies.
|
|
Academic Article
|
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
|
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies.
|
|
Academic Article
|
Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts?
|
|
Academic Article
|
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
|
|
Academic Article
|
Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come.
|
|
Academic Article
|
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
|
|
Academic Article
|
Cord blood transplants supported by unrelated donor CD34+ progenitor cells.
|
|
Academic Article
|
Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma.
|
|
Academic Article
|
Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match!
|
|
Academic Article
|
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD).
|